Anti-TNF chimeric antibody fragments
AssigneesCentocor, Inc., New York University
InventorsJunming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Life of this patent
Estimating the term…
Abstract
Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.
Claims24
An anti-TNFα chimeric antibody fragment which competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα and (ii) binds to a neutralizing epitope of human TNFα in vivo with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.
A TNFα binding fragment of anti-TNFα chimeric monoclonal antibody cA2 which comprises the variable region of monoclonal antibody A2 (ATCC Accession No. PTA-7045).
6-7. (canceled)
An anti-TNFα chimeric antibody fragment which comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3 and SEQ ID NO:
- 5.
(canceled)
Dependencies are inferred from the claim text.